
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Ten quiz questions to assess your knowledge on common symptoms and treatments for bipolar disorders.
Which of the below antipsychotics have FDA approval to treat bipolar disorders?






